Get Diamond plan for FREE

    logo

    Morphic Holding, Inc. (MORF)

    Price:

    56.99 USD

    ( + 0.02 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    MORF
    Name
    Morphic Holding, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    56.990
    Market Cap
    2.862B
    Enterprise value
    1.168B
    Currency
    USD
    Ceo
    Praveen P. Tipirneni
    Full Time Employees
    128
    Ipo Date
    2019-06-27
    City
    Waltham
    Address
    35 Gatehouse Drive, A2

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    BioNTech SE

    VALUE SCORE:

    6

    Symbol
    BNTX
    Market Cap
    22.626B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    3.694B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    12

    Symbol
    HRMY
    Market Cap
    1.624B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -15.884
    P/S
    5.494k
    P/B
    3.466
    Debt/Equity
    0.003
    EV/FCF
    -24.712
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    5.386k
    Earnings yield
    -0.063
    Debt/assets
    0.003
    FUNDAMENTALS
    Net debt/ebidta
    0.317
    Interest coverage
    0
    Research And Developement To Revenue
    269.451
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.011
    Capex to revenue
    2.382
    Capex to depreciation
    1.137
    Return on tangible assets
    -0.211
    Debt to market cap
    0.001
    Piotroski Score
    2.000
    FUNDAMENTALS
    PEG
    -0.159
    P/CF
    -21.510
    P/FCF
    -25.207
    RoA %
    -21.051
    RoIC %
    -25.550
    Gross Profit Margin %
    -109.405
    Quick Ratio
    28.936
    Current Ratio
    28.936
    Net Profit Margin %
    -29.193k
    Net-Net
    16.014
    FUNDAMENTALS PER SHARE
    FCF per share
    -2.679
    Revenue per share
    0.012
    Net income per share
    -3.588
    Operating cash flow per share
    -2.649
    Free cash flow per share
    -2.679
    Cash per share
    16.616
    Book value per share
    16.443
    Tangible book value per share
    16.443
    Shareholders equity per share
    16.443
    Interest debt per share
    0.055
    TECHNICAL
    52 weeks high
    57.000
    52 weeks low
    19.345
    Current trading session High
    57.000
    Current trading session Low
    56.970
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    CA
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -22.358
    logo

    Country
    SE
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -20.839
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -22.942
    logo

    Country
    CA
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -14.900
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -14.083
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -25.047
    logo

    Country
    DE
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -11.637
    logo

    Country
    GB
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -12.178
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -16.436
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -16.442
    DESCRIPTION

    Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

    NEWS
    https://images.financialmodelingprep.com/news/lilly-completes-acquisition-of-morphic-to-improve-outcomes-and-expand-20240816.jpg
    Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

    prnewswire.com

    2024-08-16 08:38:00

    Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).

    https://images.financialmodelingprep.com/news/eli-lilly-stock-finishes-lower-after-news-of-bond-20240812.jpg
    Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal

    investopedia.com

    2024-08-12 18:01:19

    Eli Lilly (LLY) shares finished Monday lower after a back-and-forth session in which an analyst upgrade sent them higher before news of $5 billion in bond sales pulled them into the red.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240811.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Clients to Contact the Firm!

    accesswire.com

    2024-08-11 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-an-20240809.jpg
    MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!

    accesswire.com

    2024-08-09 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE:LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/calling-all-morphic-holding-inc-morf-investors-contact-bronstein-gewirtz-20240808.jpg
    Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

    globenewswire.com

    2024-08-08 16:00:00

    NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240808.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!

    accesswire.com

    2024-08-08 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240807.jpg
    MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

    accesswire.com

    2024-08-07 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-an-20240806.jpg
    MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

    accesswire.com

    2024-08-06 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240805.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

    accesswire.com

    2024-08-05 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240804.jpg
    MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!

    accesswire.com

    2024-08-04 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/calling-all-morphic-holding-inc-morf-investors-contact-bronstein-20240802.jpg
    Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

    globenewswire.com

    2024-08-02 16:00:00

    NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240802.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!

    accesswire.com

    2024-08-02 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240801.jpg
    MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

    accesswire.com

    2024-08-01 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240731.jpg
    MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

    accesswire.com

    2024-07-31 10:00:00

    NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-alert-wohl-fruchter-llp-files-class-action-lawsuit-20240731.jpg
    MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California

    globenewswire.com

    2024-07-31 09:15:00

    MONSEY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Wohl & Fruchter LLP announces that on July 25, 2024, it filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Zappia v.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240730.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

    accesswire.com

    2024-07-30 10:00:00

    NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.